Skip to main content
Rheumatology’s Blind Spot: The Persistent Exclusion of Older Adults

In RA alone, nearly 40% of patients are now aged

Dr. John Cush RheumNow

8 months 4 weeks ago
Rheumatology’s Blind Spot: The Persistent Exclusion of Older Adults In RA alone, nearly 40% of patients are now aged 65 years or older. Yet the evidence guiding our treatment decisions continues to come from studies that rarely include them, giving rise to a fundamental https://t.co/2pqXGURQtL
Following the landmark case series by the Erlangen group, multiple cellular therapies have entered the race—each with unique targets, constructs, and mechanisms. Yet, a fundamental question remains: How deep is the B-cell depletion? In clinical practice, peripheral blood counts often serve as our surrogate for depletion. But these may only tell part of the story.
AI continues to move from research labs into rheumatology clinics, promising to reshape how inflammatory diseases are diagnosed and monitored. Ankylosing spondylitis, in particular, poses a diagnostic challenge—its early imaging findings are subtle, and radiographic changes may take years to appear and require specific musculoskeletal radiology expertise. A new deep learning model offers a glimpse into how AI could bridge this diagnostic gap.
PsA: ACR 2025 Topic Panel
Tofacitinib in AxSpA in Developing Countries

Dr. Antoni Chan reports on abstracts 0582 and abstract 0554 presented at

Dr. John Cush RheumNow

8 months 4 weeks ago
Tofacitinib in AxSpA in Developing Countries Dr. Antoni Chan reports on abstracts 0582 and abstract 0554 presented at #ACR25 https://t.co/4kTv90PhIC https://t.co/WRUBP0O21b
900,000 vs 9
It takes about 900,000 minutes to become a board-certified dermatologist. At that point, you might be very

Dr. John Cush RheumNow

9 months ago
900,000 vs 9 It takes about 900,000 minutes to become a board-certified dermatologist. At that point, you might be very skilled and well-informed. It takes less than nine minutes to make your patient feel seen, understood and reassured. If you skip the 9 minutes, you wasted the https://t.co/DBoteUTavZ
Topline results of ALLEGORY study (Genentech) - 300 pt. phase 3 DBRPCT obinuntuzumab vs PBO in active SLE w/ SRI-4 prima

Dr. John Cush RheumNow

9 months ago
Topline results of ALLEGORY study (Genentech) - 300 pt. phase 3 DBRPCT obinuntuzumab vs PBO in active SLE w/ SRI-4 primary outcome at wk 52. The anti-CD20, B-cell depleter, Rx met all efficacy endpoints primary and all key secondary endpoints. Gazyva was FDA approved last wk https://t.co/Wd6EFEjvGP
Difficult to Manage axSpA

Drs. Antoni Chan and Rodrigo Garcia Salinas discuss abstract 0584, "Difficult-to-Manage Axia

Dr. John Cush RheumNow

9 months ago
Difficult to Manage axSpA Drs. Antoni Chan and Rodrigo Garcia Salinas discuss abstract 0584, "Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns", presented at #ACR25 https://t.co/84HZojI3FJ
Not only lovely work @TheLancetRheum from @jeffsparks and friends, but they have some AI imaging work up tomorrow from t

David Liew drdavidliew

9 months ago
Not only lovely work @TheLancetRheum from @jeffsparks and friends, but they have some AI imaging work up tomorrow from the same SAIL-RA cohort, showing the spectrum of impact in all RA patients, using radiomics. Check it out #ACR25 ABST1751 @RheumNow https://t.co/TlmHOOpNNp https://t.co/P62RXI8ePQ
A 15-year-old girl has short stature and the hand finding shown . Labs show ↓Ca²⁺, ↑PO₄³⁻, ↑PTH.
What is t

Dr. Nikhil Agrawal DrNikhilMD

9 months ago
A 15-year-old girl has short stature and the hand finding shown . Labs show ↓Ca²⁺, ↑PO₄³⁻, ↑PTH. What is the most likely diagnosis? https://t.co/afPUeaqfZT
×